143 related articles for article (PubMed ID: 27669207)
1. Development of an Innovative Intradermal siRNA Delivery System Using a Combination of a Functional Stearylated Cytoplasm-Responsive Peptide and a Tight Junction-Opening Peptide.
Ibaraki H; Kanazawa T; Takashima Y; Okada H; Seta Y
Molecules; 2016 Sep; 21(10):. PubMed ID: 27669207
[TBL] [Abstract][Full Text] [Related]
2. Development of a Liquid Crystal Formulation that Can Penetrate the Stratum Corneum for Intradermal Delivery of Small Interfering RNA.
Kawai M; Ibaraki H; Takashima Y; Kanazawa T; Okada H
Mol Pharm; 2021 Mar; 18(3):1038-1047. PubMed ID: 33395310
[TBL] [Abstract][Full Text] [Related]
3. Transdermal anti-nuclear kappaB siRNA therapy for atopic dermatitis using a combination of two kinds of functional oligopeptide.
Ibaraki H; Kanazawa T; Takashima Y; Okada H; Seta Y
Int J Pharm; 2018 May; 542(1-2):213-220. PubMed ID: 29551748
[TBL] [Abstract][Full Text] [Related]
4. Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002.
Uchida T; Kanazawa T; Takashima Y; Okada H
Chem Pharm Bull (Tokyo); 2011; 59(2):196-201. PubMed ID: 21297299
[TBL] [Abstract][Full Text] [Related]
5. Anti-RelA siRNA-Encapsulated Flexible Liposome with Tight Junction-Opening Peptide as a Non-invasive Topical Therapeutic for Atopic Dermatitis.
Ibaraki H; Kanazawa T; Kurano T; Oogi C; Takashima Y; Seta Y
Biol Pharm Bull; 2019; 42(7):1216-1225. PubMed ID: 31257297
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002.
Uchida T; Kanazawa T; Kawai M; Takashima Y; Okada H
J Pharmacol Exp Ther; 2011 Aug; 338(2):443-50. PubMed ID: 21531792
[TBL] [Abstract][Full Text] [Related]
7. Overcoming thickened pathological skin in psoriasis via iontophoresis combined with tight junction-opening peptide AT1002 for intradermal delivery of NF-κB decoy oligodeoxynucleotide.
Fukuta T; Tanaka D; Inoue S; Michiue K; Kogure K
Int J Pharm; 2021 Jun; 602():120601. PubMed ID: 33905867
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive delivery of siRNA into the epidermis by iontophoresis using an atopic dermatitis-like model rat.
Kigasawa K; Kajimoto K; Hama S; Saito A; Kanamura K; Kogure K
Int J Pharm; 2010 Jan; 383(1-2):157-60. PubMed ID: 19732811
[TBL] [Abstract][Full Text] [Related]
9. Is the Fractional Laser Still Effective in Assisting Cutaneous Macromolecule Delivery in Barrier-Deficient Skin? Psoriasis and Atopic Dermatitis as the Disease Models.
Lee WR; Shen SC; Sung CT; Liu PY; Fang JY
Pharm Res; 2018 Apr; 35(7):128. PubMed ID: 29700662
[TBL] [Abstract][Full Text] [Related]
10. Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer.
Hsu T; Mitragotri S
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15816-21. PubMed ID: 21903933
[TBL] [Abstract][Full Text] [Related]
11. Topical delivery of siRNA into skin using SPACE-peptide carriers.
Chen M; Zakrewsky M; Gupta V; Anselmo AC; Slee DH; Muraski JA; Mitragotri S
J Control Release; 2014 Apr; 179():33-41. PubMed ID: 24434423
[TBL] [Abstract][Full Text] [Related]
12. Development of edge-activated liposomes for siRNA delivery to human basal epidermis for melanoma therapy.
Dorrani M; Garbuzenko OB; Minko T; Michniak-Kohn B
J Control Release; 2016 Apr; 228():150-158. PubMed ID: 26965957
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of topical small interfering RNA delivery and expression by low-fluence erbium:YAG laser pretreatment of skin.
Lee WR; Shen SC; Zhuo RZ; Wang KC; Fang JY
Hum Gene Ther; 2009 Jun; 20(6):580-8. PubMed ID: 19239381
[TBL] [Abstract][Full Text] [Related]
14. Enolase-1 expression in the stratum corneum is elevated with parakeratosis of atopic dermatitis and disrupts the cellular tight junction barrier in keratinocytes.
Tohgasaki T; Ozawa N; Yoshino T; Ishiwatari S; Matsukuma S; Yanagi S; Fukuda H
Int J Cosmet Sci; 2018 Apr; 40(2):178-186. PubMed ID: 29430682
[TBL] [Abstract][Full Text] [Related]
15. The role of tight junctions in skin barrier function and dermal absorption.
Bäsler K; Bergmann S; Heisig M; Naegel A; Zorn-Kruppa M; Brandner JM
J Control Release; 2016 Nov; 242():105-118. PubMed ID: 27521894
[TBL] [Abstract][Full Text] [Related]
16. Impaired Tight Junctions in Atopic Dermatitis Skin and in a Skin-Equivalent Model Treated with Interleukin-17.
Yuki T; Tobiishi M; Kusaka-Kikushima A; Ota Y; Tokura Y
PLoS One; 2016; 11(9):e0161759. PubMed ID: 27588419
[TBL] [Abstract][Full Text] [Related]
17. A simple, noninvasive and efficient method for transdermal delivery of siRNA.
Lin CM; Huang K; Zeng Y; Chen XC; Wang S; Li Y
Arch Dermatol Res; 2012 Mar; 304(2):139-44. PubMed ID: 22009459
[TBL] [Abstract][Full Text] [Related]
18. Tight junction protein claudin-4 is modulated via ΔNp63 in human keratinocytes.
Kubo T; Sugimoto K; Kojima T; Sawada N; Sato N; Ichimiya S
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):205-11. PubMed ID: 25449274
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of tight junction barrier integrity in cell turnover and skin diseases.
Yokouchi M; Kubo A
Exp Dermatol; 2018 Aug; 27(8):876-883. PubMed ID: 30019465
[TBL] [Abstract][Full Text] [Related]
20. Epidermal tight junction barrier function is altered by skin inflammation, but not by filaggrin-deficient stratum corneum.
Yokouchi M; Kubo A; Kawasaki H; Yoshida K; Ishii K; Furuse M; Amagai M
J Dermatol Sci; 2015 Jan; 77(1):28-36. PubMed ID: 25511077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
